Single-cell hdWGCNA identifies checkpoint inhibitor pneumonitis-linked CD4+ T-cell subsets driving immunotherapy response and prognosis in lung cancer.
Specific immune cells predict both who benefits from immunotherapy and who may suffer severe side effects, potentially improving treatment decisions.
Single-cell hdWGCNA analysis identifies CD4+ T-cell subsets, including BIRC3+ cells, that are linked to both checkpoint inhibitor pneumonitis pathogenesis and immunotherapy prognosis in lung adenocarcinoma. These immune cell populations may serve as dual biomarkers for predicting treatment response and immunotherapy-related pulmonary toxicity.
What the study was
- Study design
- single-cell RNA sequencing analysis with cohort validation
- Population
- Lung adenocarcinoma patients
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Journal of cancer research and clinical oncology
Why it surfaced
Identifies immune mechanism linking ICI complication (CIP) with prognosis in lung cancer; clinically relevant for patient selection and toxicity management in checkpoint therapy; scRNA approach adds mechanistic depth.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.